NCT02587598: Study of INCB053914 in Subjects With Advanced Malignancies

NCT02587598
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: MBC patients are only eligible for Parts 1 & 2
Exclusions: 
https://ClinicalTrials.gov/show/NCT02587598

Comments are closed.

Up ↑